WELA:XETRA:XETRA-Amundi MSCI ACWI SRI PAB UCITS ETF DR USD Acc EUR (EUR)

ETF | Others |

Last Closing

USD 12.616

Change

-0.30 (-2.31)%

Market Cap

N/A

Volume

0.03M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict
Created with Highstock 5.0.6

Very Bullish

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
WELA:XETRA
Relative Returns (From:    To: 2025-01-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CA1:XETRA Circus SE

-1.00 (-4.90%)

USD 0.51B
7V0:XETRA Darwin AG

+1.00 (+3.85%)

USD 0.08B
TY3S:XETRA WisdomTree US Treasuries 10Y 3..

+2.18 (+2.02%)

N/A
AXTZ:XETRA 21Shares Tezos staking ETP

+0.03 (+0.60%)

N/A
42FB:XETRA AI/ML Innovations Inc.

N/A

N/A
ABCH:XETRA 21Shares Bitcoin Cash ETP

-0.29 (-2.13%)

N/A
8PSB:XETRA Invesco Physical Markets PLC O

+0.21 (+0.71%)

N/A
BTIC:XETRA Invesco Physical Bitcoin ETN E..

-1.02 (-1.12%)

N/A
2BTD:XETRA 2BTD

-0.30 (-0.91%)

N/A
8PSC:XETRA Source Physical Palladium P

-1.47 (-1.62%)

N/A

ETFs Containing WELA:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.10% 32% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.10% 32% F 32% F
Trailing 12 Months  
Capital Gain 15.91% 66% D+ 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.91% 66% D+ 66% D+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 9.01% 60% D- 60% D-
Dividend Return 9.01% 59% D- 58% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 9.11% 66% D+ 73% C
Risk Adjusted Return 98.93% 86% B+ 88% B+
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike